GlobeNewswire: Arbor Biotechnologies Inc Contains the last 10 of 28 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:11:16ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/01/03/2803274/0/en/4DMT-and-Arbor-Biotechnologies-Establish-Partnership-to-Co-Develop-and-Co-Commercialize-Next-Generation-Genetic-Medicines-for-CNS-Diseases.html?f=22&fvtc=4&fvtv=463834DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases2024-01-03T13:01:00Z<![CDATA[EMERYVILLE, Calif. and CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, and Arbor Biotechnologies, Inc. (Arbor), a next-generation gene editing company developing potentially curative therapeutics for patients with serious diseases based on its proprietary and modular toolbox of DNA-editing technologies, today announced a strategic partnership focused on advancing new AAV-based gene-editing therapies for central nervous system (CNS) diseases with high unmet medical needs in both rare and common disease populations. 4DMT and Arbor will co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates, with the costs and profits shared evenly based on mutually agreed plans.]]>https://www.globenewswire.com/news-release/2023/11/07/2774902/0/en/Arbor-Biotechnologies-Appoints-Industry-Veteran-R-Nolan-Townsend-to-Board-of-Directors.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies Appoints Industry Veteran R. Nolan Townsend to Board of Directors2023-11-07T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of R. Nolan Townsend to the Company’s Board of Directors. Mr. Townsend is the Chief Executive Officer of LEXEO Therapeutics, a clinical stage gene therapy company advancing candidates for genetically defined cardiovascular diseases and a genetically defined sub-group of Alzheimer’s disease.]]>https://www.globenewswire.com/news-release/2023/08/29/2733230/0/en/Arbor-Biotechnologies-Appoints-Ajim-Tamboli-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer2023-08-29T11:00:00Z<![CDATA[CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Ajim Tamboli, CFA, as its Chief Financial Officer. Mr. Tamboli brings over 24 years of health care experience to the role, joining Arbor from Monte Rosa Therapeutics, where he served as Chief Financial Officer. He was responsible for leading private and public fund raises of over $465M, including an upsized $255M IPO in 2021.]]>https://www.globenewswire.com/news-release/2023/08/07/2719560/0/en/Arbor-Biotechnologies-Appoints-Deanna-M-Petersen-as-Chief-Business-Officer.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer2023-08-07T11:00:00Z<![CDATA[CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Deanna M. Petersen, MBA, as its Chief Business Officer. Ms. Petersen joins Arbor from AVROBIO, Inc., where she served as Chief Business Officer, responsible for spearheading their early commercial and corporate growth strategy, leading business development activities and building an industry-leading lysosomal storage disorder gene therapy pipeline.]]>https://www.globenewswire.com/news-release/2023/05/23/2674132/0/en/Arbor-Biotechnologies-to-Present-at-the-Stifel-2023-Tailoring-Genes-Genetic-Medicines-Day.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies to Present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day2023-05-23T11:00:00Z<![CDATA[CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced Devyn Smith, Ph.D., Arbor’s Chief Executive Officer, will present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day. The event will be held on Tuesday, May 30, 2023, and will be livestreamed.]]>https://www.globenewswire.com/news-release/2023/05/02/2659809/0/en/Arbor-Biotechnologies-Announces-Presentations-at-the-2023-Annual-Meeting-of-the-American-Society-of-Gene-Cell-Therapy.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies Announces Presentations at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy2023-05-02T20:30:00Z<![CDATA[CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that three abstracts were selected for poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being held from May 16-20, 2023, in Los Angeles, CA.]]>https://www.globenewswire.com/news-release/2023/04/12/2645176/0/en/Arbor-Biotechnologies-Appoints-Dr-Daniel-Ory-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies Appoints Dr. Daniel Ory as Chief Medical Officer2023-04-12T11:00:00Z<![CDATA[CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic editing medicines, today announced the appointment of Daniel Ory, M.D., as Chief Medical Officer. Dr. Ory joins Arbor from Casma Therapeutics, a Third Rock Ventures start up, where he served most recently as Chief Medical Officer, responsible for overseeing its muscular dystrophy and rare oncology programs.]]>https://www.globenewswire.com/news-release/2023/04/06/2642398/0/en/Arbor-Biotechnologies-to-Present-at-2023-Cell-Gene-Meeting-on-the-Med.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies to Present at 2023 Cell & Gene Meeting on the Med2023-04-06T11:00:00Z<![CDATA[CAMBRIDGE, Mass., April 06, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that Devyn Smith, Ph.D., Arbor’s Chief Executive Officer and the Chairman of Alliance for Regenerative Medicine, will give welcoming remarks and present at the annual Cell & Gene Meeting on the Med. The congress will be held April 12-14 in Barcelona, Spain and livestreamed globally.]]>https://www.globenewswire.com/news-release/2023/01/11/2586897/0/en/Arbor-Biotechnologies-Announces-Expanded-Strategic-Partnership-with-Vertex-Now-Extending-to-Precision-Gene-Editing-Using-Reverse-Transcriptase.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies Announces Expanded Strategic Partnership with Vertex, Now Extending to Precision Gene Editing Using Reverse Transcriptase2023-01-11T12:00:00Z<![CDATA[Agreement provides access to Arbor’s precision editing capabilities Agreement provides access to Arbor’s precision editing capabilities]]>https://www.globenewswire.com/news-release/2023/01/04/2582752/0/en/Arbor-Biotechnologies-to-Present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=46383Arbor Biotechnologies to Present at the 41st Annual J.P. Morgan Healthcare Conference2023-01-04T12:00:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that its Chief Executive Officer, Devyn Smith, Ph.D., will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 1:30 p.m. PT.]]>